This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al (2014). American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg, 72:1938–1956. Doi: 10.1016/j.joms.2014.04.031.RuggieroSLDodsonTBFantasiaJGooddayRAghalooTMehrotraB2014American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update721938195610.1016/j.joms.2014.04.031Open DOISearch in Google Scholar
Owosho AA, Blanchard A, Levi L, Kadempour A, Rosenberg H, Yom SK, et al (2016). Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients. J Craniomaxillofac Surg 44:265–70, doi: 10.1016/j.jcms.2015.12.005.OwoshoAABlanchardALeviLKadempourARosenbergHYomSK2016Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients442657010.1016/j.jcms.2015.12.005Open DOISearch in Google Scholar
Schiodt M, Vadhan-Raj S, Chambers MS, Nicolatou-Galitis O, Politis C, Coropciuc R, et al (2018). A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer. Support Care Cancer 26: 1905–1915, Doi: 10.1007/s00520-017-4003-2.SchiodtMVadhan-RajSChambersMSNicolatou-GalitisOPolitisCCoropciucR2018A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer261905191510.1007/s00520-017-4003-2Open DOISearch in Google Scholar
Migliorati CA, Brennan MT, Peterson DE (2019). Medication-Related Osteonecrosis of the Jaws.J Natl Cancer Inst Monogr 53, doi: 10.1093/jncimonographs/lgz009.MiglioratiCABrennanMTPetersonDE2019Medication-Related Osteonecrosis of the Jaws5310.1093/jncimonographs/lgz009Open DOISearch in Google Scholar
Marx RE (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 61:115–117.MarxRE2003Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic61115117Search in Google Scholar
Migliorati CA (2003). Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253–4254.MiglioratiCA2003Bisphosphonates and oral cavity avascular bone necrosis2142534254Search in Google Scholar
Wang J, Goodger NM, Pogrel MA (2003). Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61:1104–7.WangJGoodgerNMPogrelMA2003Osteonecrosis of the jaws associated with cancer chemotherapy6111047Search in Google Scholar
Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, et al (2010). Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:191–188.GuarneriVMilesDRobertNDiérasVGlaspyJSmithI2010Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer122191188Search in Google Scholar
Fusco V, Santini D, Armento G, Tonini G, Campisi G (2016). Osteonecrosis of the jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opinion on Drug Safety 15:7, 925–935.FuscoVSantiniDArmentoGToniniGCampisiG2016Osteonecrosis of the jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology157925935Search in Google Scholar
Pimolbutr K, Porter S, Fedele S (2018). Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naïve patient: a comprehensive review of the literature. Bio Med Res Int 14. Doi: 10.1155/2018/8071579.PimolbutrKPorterSFedeleS2018Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naïve patient: a comprehensive review of the literature1410.1155/2018/8071579Open DOISearch in Google Scholar
Mahedi Mohamed HA, Nor Nielsen CE, Schiodt M (2018). Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of seven cases from the Copenhagen ONJ cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 125:157–163, https://doi.org/10.1016/j.oooo.2017.10.010.Mahedi MohamedHANor NielsenCESchiodtM2018Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of seven cases from the Copenhagen ONJ cohort125157163https://doi.org/10.1016/j.oooo.2017.10.010.Search in Google Scholar
Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D et al (2019a). Osteonecrosis of the jaw related to non-antiresorptive medications: A systematic review. Support Care Cancer 27:383–394, Doi: 10.1007/s00520-018-4501-x.Nicolatou-GalitisOKouriMPapadopoulouEVardasEGalitiD2019aOsteonecrosis of the jaw related to non-antiresorptive medications: A systematic review2738339410.1007/s00520-018-4501-xOpen DOISearch in Google Scholar
Christodoulou C, Pervena A, Klouvas G, et al (2009). Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209–211.ChristodoulouCPervenaAKlouvasG2009Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone76209211Search in Google Scholar
Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al (2012). Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 6:1665–71.BeuselinckBWolterPKaradimouAElaidiRDumezHRogiersA2012Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases6166571Search in Google Scholar
Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F (2013). Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 71:1532–40.Smidt-HansenTFolkmarTBFodeKAgerbaekMDonskovF2013Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma71153240Search in Google Scholar
Van Cann T, Loyson T, Verbiest A, Clement PM, Becher O, Willems L, et al (2018). Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26: 869–878. DOI 10.1007/s00520-017-3903-5.Van CannTLoysonTVerbiestAClementPMBecherOWillemsL2018Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors2686987810.1007/s00520-017-3903-5Open DOISearch in Google Scholar
Yarom N, Lazarovizi TS, Whitefield S, Weissman et al (2018). Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab. Oral Surg Oral Med Oral Pathol Oral Radiol 125;27–30.YaromNLazaroviziTSWhitefieldSWeissman2018Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumab1252730Search in Google Scholar
Srivastava A, Nogueras Gonzalez GM, Geng Y, Won A M, Cabanillas ME, Naing A, et al (2021). Prevalence of medication related osteonecrosis of the jaw in patients with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer 29:2305–2317.SrivastavaANogueras GonzalezGMGengYWonA MCabanillasMENaingA2021Prevalence of medication related osteonecrosis of the jaw in patients with sequential antiresorptive drugs: systematic review and meta-analysis2923052317Search in Google Scholar
Schiodt M, Otto S, Fedele S, Bedogni A, Nicolatou-Galitis O, Guggenberger R, et al (2019). Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges. Oral Dis 25:1815–1821, doi: 10.1111/odi.13160.SchiodtMOttoSFedeleSBedogniANicolatou-GalitisOGuggenbergerR2019Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges251815182110.1111/odi.13160Open DOISearch in Google Scholar
Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vesconi P, Mafredi M, et al (2010). Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series. Am J Med 123:1060–1064.FedeleSPorterSRD'AiutoFAljohaniSVesconiPMafrediM2010Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series12310601064Search in Google Scholar
Patel S, Choyee S, Uyanne J, Nguyen AL, Lee P, Sedghizadehet PP, et al (2012). Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis 18: 625–632.PatelSChoyeeSUyanneJNguyenALLeePSedghizadehetPP2012Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines18625632Search in Google Scholar
Schiodt M, Reibel J, Oturai P, Kofod T (2014). Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol 117:204–213, Doi: 10.1016/j.oooo.2013.10.010.SchiodtMReibelJOturaiPKofodT2014Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system11720421310.1016/j.oooo.2013.10.010Open DOISearch in Google Scholar
Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, et al (2015). Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg, 53:13–17. Doi: 10.1016/j.bjoms.2014.09.001.FedeleSBedogniGScolettaMFaviaGColellaGAgrilloA2015Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed53131710.1016/j.bjoms.2014.09.001Open DOISearch in Google Scholar
Yarom N, Shapiro CL, Peterson DE, Van Poznac CH, Bohlke K, Ruggiero SL, et al (2019). Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol 37:2270–2290, doi.org/10.1200/JCO.19.01186.YaromNShapiroCLPetersonDEVan PoznacCHBohlkeKRuggieroSL2019Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline3722702290doi.org/10.1200/JCO.19.01186.Search in Google Scholar
Saad F, Brown JE, Van Poznak C, et al (2012). Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol: official journal of the European Society for Medical Oncology / ESMO 23: 1341–1347.SaadFBrownJEVan PoznakC2012Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases2313411347Search in Google Scholar
Rugani P, Walter C, Kirnbauer B, Achan S, Begus-Nahrman Y, Jakse N (2016). Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dentistry Journal 32; doi: 10.3390/dj4040032.RuganiPWalterCKirnbauerBAchanSBegus-NahrmanYJakseN2016Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma3210.3390/dj4040032Open DOISearch in Google Scholar
Fung PPL, Bedogni G, Bedogni A, Petrie A, Porter S, Campisi G et al (2017). Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicenter retrospective cohort study. Oral Dis, 23:477–483, Doi: 10.1111/odi.12632.FungPPLBedogniGBedogniAPetrieAPorterSCampisiG2017Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicenter retrospective cohort study2347748310.1111/odi.12632Open DOISearch in Google Scholar
Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M. (2018). Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment Reviews, 69, 177–187, Doi: 10.1016/j.ctrv.2018.06.007.OttoSPautkeCVan den WyngaertTNiepelDSchiodtM2018Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases6917718710.1016/j.ctrv.2018.06.007Open DOISearch in Google Scholar
Hallmer F, Bjarnadottir O, Gotric B, Malmstrom P, Anderson G (2020). Incidence and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol 130:252–257.HallmerFBjarnadottirOGotricBMalmstromPAndersonG2020Incidence and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study130252257Search in Google Scholar
Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, et al (2022). Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study. Supportive Care Cancer 30:4505–4514.HataHImamachiKUedaMMatsuzakaMHiragaHOsanaiT2022Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study3045054514Search in Google Scholar
Ikesue H, Doi K, Morimoto M, Hirabatake M, Muroi N, Yamamoto S, et al (2022). Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. Support Care Cancer 30:2341–2348.IkesueHDoiKMorimotoMHirabatakeMMuroiNYamamotoS2022Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis3023412348Search in Google Scholar
Fusco V, Campisi G, Bedogni A (2022). One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). Support Care Cancer, doi.org/10.1007/s00520-022-06982-y.FuscoVCampisiGBedogniA2022One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)doi.org/10.1007/s00520-022-06982-y.Search in Google Scholar
Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, et al (2018). Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 125:547–551.HiguchiTSogaYMuroMKajizonoMKitamuraYSendoT2018Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw125547551Search in Google Scholar
Yazdi PM, Schiodt M. (2015). Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 119:416–422, doi: 10.1016/j.oooo.2014.12.024.YazdiPMSchiodtM2015Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ Cohort11941642210.1016/j.oooo.2014.12.024Open DOISearch in Google Scholar
Matsuo A, Hamada H, Kaise H, Chikazu D, Yamada K, Kohno N (2014). Characteristics of the early stages of intravenous bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer. Acta Odontol Scand 72: 656–663.MatsuoAHamadaHKaiseHChikazuDYamadaKKohnoN2014Characteristics of the early stages of intravenous bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer72656663Search in Google Scholar
Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O, et al. (2015). Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development? J Craniomaxillofac Surg 43: 847–854, Doi: 10.1016/j.jcms.2015.03.039.OttoSTroltzschMJambrovicVPanyaSProbstFRistowO2015Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?4384785410.1016/j.jcms.2015.03.039Open DOISearch in Google Scholar
Kamimura M, Taguch A, Komatsu M, Koiwai H, Ashizawa R, Ichinose A, et al (2018). Long waiting before tooth extraction may increase delayed wound healing in elderly Japanese. Osteoporosis Intern doi: 10.1007/s00198-018-4775-3.KamimuraMTaguchAKomatsuMKoiwaiHAshizawaRIchinoseA2018Long waiting before tooth extraction may increase delayed wound healing in elderly Japanese10.1007/s00198-018-4775-3Open DOISearch in Google Scholar
Soutome S, Hayashida S, Funahara M, Sakamoto Y, Kojima Y, Yamamoto S, et al (2018). Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor? PLOS One, doi: .org/10.1371/journal.pone.0201343.SoutomeSHayashidaSFunaharaMSakamotoYKojimaYYamamotoS2018Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?doi: .org/10.1371/journal.pone.0201343.Search in Google Scholar
Nicolatou-Galitis O, Papadopoulou E, Vardas E, Kouri M, Galiti D, Galitis E, et al (2020). Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis. 2020 Jul;26(5):955–966. doi: 10.1111/odi.13294. Epub 2020 Mar 3. PMID: 32011077.Nicolatou-GalitisOPapadopoulouEVardasEKouriMGalitiDGalitisE2020Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents2020Jul26595596610.1111/odi.13294Epub 2020 Mar 3. PMID: 32011077.Open DOISearch in Google Scholar
Ristow O, Ruckschlob T, Moratin J, Muller M, et al (2021a). Wound closure and alveoloplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot study. Oral Dis 27:532–546.RistowORuckschlobTMoratinJMullerM2021aWound closure and alveoloplasty after preventive tooth extractions in patients with antiresorptive intake-A randomized pilot study27532546Search in Google Scholar
Nicolatou-Galitis O, Schiodt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al (2019b). Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis and management. Oral Surg Oral Med Oral Pathol Oral Radiol 127:117–135. Doi: 10.1016/j.oooo.2018.09.008Nicolatou-GalitisOSchiodtMMendesRARipamontiCHopeSDrudge-CoatesL2019bMedication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis and management12711713510.1016/j.oooo.2018.09.008Open DOISearch in Google Scholar
Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al (2017). Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017 Jan;35(1):6–19. doi: 10.1007/s00774-016-0810-7.YonedaTHaginoHSugimotoTOhtaHTakahashiSSoenS2017Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw2017Jan35161910.1007/s00774-016-0810-7Open DOISearch in Google Scholar
Dutra KL, Haas LF, Zimmermann GS, et al (2019). Prevalence of radiographic findings on jaws exposed to antiresorptive therapy: a meta-analysis. Dentomaxillofac Radiol 48 doi: 10.1259/dmfr.20180112.DutraKLHaasLFZimmermannGS2019Prevalence of radiographic findings on jaws exposed to antiresorptive therapy: a meta-analysis4810.1259/dmfr.20180112Open DOISearch in Google Scholar
Moreno-Rabie C, Gaeta-Araujo H, Oliveira-Santos C, Politis C, et al (2020). Early imaging signs of the use of antiresorptive medication and MRONJ: a systematic review. Clin Oral Investig 24:2973–2989.Moreno-RabieCGaeta-AraujoHOliveira-SantosCPolitisC2020Early imaging signs of the use of antiresorptive medication and MRONJ: a systematic review2429732989Search in Google Scholar
Wongratwanich P, Shimabukuro K, Konishi M, Nagasaki T, Ohtsuka M, Suei Y, Nakamoto T, Verdonschot RG, Kanesaki T, Sutthiprapaporn P, Kakimoto N (2021). Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review. Dentomaxillofac Radiol. 1;50(6):20200417. doi: 10.1259/dmfr.20200417.WongratwanichPShimabukuroKKonishiMNagasakiTOhtsukaMSueiYNakamotoTVerdonschotRGKanesakiTSutthiprapapornPKakimotoN2021Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review1;50620200417.10.1259/dmfr.20200417Open DOISearch in Google Scholar
Tsiklakis K. and Karayanni A. (2018). Oral Diagnosis and Radiology. Athens, Greece, Litsas Medical editions.TsiklakisK.KarayanniA.2018Athens, GreeceLitsas Medical editionsSearch in Google Scholar
Bedogni A, Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, et al (2014). Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease. Br J Oral Maxillofac Surg 52: 603–608, Doi: 10.1016/j.bjoms.2014.04.009.BedogniAFedeleSBedogniGScolettaMFaviaGColellaG2014Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease5260360810.1016/j.bjoms.2014.04.009Open DOISearch in Google Scholar
Ristow O, Schung G, Smielowksi M, Moratin J, Pilz M, Engel M, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone changes before tooth extractions in patients with antiresorptive intake. Oral Dis. 2021 Oct 12. doi: 10.1111/odi.14048.RistowOSchungGSmielowksiMMoratinJPilzMEngelM2021bDiagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone changes before tooth extractions in patients with antiresorptive intake2021Oct1210.1111/odi.14048Open DOISearch in Google Scholar
Cardoso CL, Barros CA, Curra C, Fernandes LM, Franzolin SO, Júnior JS, et al (2017). Radiographic Findings in Patients with Medication-Related Osteonecrosis of the Jaw. Int J Dent 2017:3190301.CardosoCLBarrosCACurraCFernandesLMFranzolinSOJúniorJS2017Radiographic Findings in Patients with Medication-Related Osteonecrosis of the Jaw20173190301.Search in Google Scholar
Lentzen MP, Buller J, Riekert M, Grandoch A, Kreppel M, Zöller JE, Zirk M (2021). Bisphosphonate application and volumetric effects on MRONJ lesions. J Craniomaxillofac Surg. 49(6):501–507. doi: 10.1016/j.jcms.2021.01.014.LentzenMPBullerJRiekertMGrandochAKreppelMZöllerJEZirkM2021Bisphosphonate application and volumetric effects on MRONJ lesions49650150710.1016/j.jcms.2021.01.014Open DOISearch in Google Scholar
Soundia A, Hadaya D, Mallya SM, Aghaloo TL, Tetradis S (2018). Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol 126:537–544, doi: 10.1016/j.oooo.2018.08.005.SoundiaAHadayaDMallyaSMAghalooTLTetradisS2018Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws12653754410.1016/j.oooo.2018.08.005Open DOISearch in Google Scholar
Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, et al (2021). Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Support Care Cancer 29:2509–2517.KizubDAMiaoJSchubertMMPatersonAHGClemonsMDeesEC2021Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)2925092517Search in Google Scholar
Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al (2009). Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–129.DimopoulosMAKastritisEBamiaCMelakopoulosIGikaDRoussouM2009Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid20117129Search in Google Scholar
Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al (2009). Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145, doi: 10.1093/annonc/mdn526.RipamontiCIManiezzoMCampaTFagnoniEBrunelliCSaibeneG2009Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan2013714510.1093/annonc/mdn526Open DOISearch in Google Scholar
Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al (2011). American Society of Clinical Oncology Executive summary of the clinical Practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221–1227, doi: 10.1200/jco.2010.32.5209.Van PoznakCHTeminSYeeGCJanjanNABarlowWEBiermannJS2011American Society of Clinical Oncology Executive summary of the clinical Practice guideline update on the role of bone-modifying agents in metastatic breast cancer291221122710.1200/jco.2010.32.5209Open DOISearch in Google Scholar
Villafuerte KRV, Dantas Ft, Taba M Jr, Messora M, Candido dos Reis F, Carrara HHA et al (2021). Effects of non-surgical periodontal therapy on the cytokine profile in gingival crevicular fluid of breast cancer patients with periodontitis undergoing chemotherapy. Support Care Cancer 29:7505–7513.VillafuerteKRVDantasFtTabaMJrMessoraMCandido dos ReisFCarraraHHA2021Effects of non-surgical periodontal therapy on the cytokine profile in gingival crevicular fluid of breast cancer patients with periodontitis undergoing chemotherapy2975057513Search in Google Scholar
Coropciuc RG, Grisar K, Aerden T, Schol M, Schoenaers J, Politis C (2017). Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2. Br J Oral Maxillofac Surg 55:787–792.CoropciucRGGrisarKAerdenTScholMSchoenaersJPolitisC2017Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 255787792Search in Google Scholar
Hayashida S, Soutome S, Yanamoto S, Fujita S, Hasegawa T, Komori T, Kojima Y, Miyamoto H, et al (2017). Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis. J Bone Miner Res 32:2022–2029, doi: 10.1002/jbmr.3191.HayashidaSSoutomeSYanamotoSFujitaSHasegawaTKomoriTKojimaYMiyamotoH2017Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis322022202910.1002/jbmr.3191Open DOISearch in Google Scholar
Ramaglia L, Guida A, Lorio-Siciliano V, Cuozzo A, Blasi A, Sculean A (2018). Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol. Clin Oral Investig, 22:597–615, Doi: 10.1007/s00784-017-2325-6.RamagliaLGuidaALorio-SicilianoVCuozzoABlasiASculeanA2018Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol2259761510.1007/s00784-017-2325-6Open DOISearch in Google Scholar
Yamada SI, Kurita H, Kondo E, Suzuki S, Nishimaki F, Yoshimura N, et al (2019). Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review. Clin Oral Investig 23:3203–3211, doi: 10.1007/s00784-018-2743-0.YamadaSIKuritaHKondoESuzukiSNishimakiFYoshimuraN2019Treatment outcomes and prognostic factors of medication-related osteonecrosis of the jaw: a case- and literature-based review233203321110.1007/s00784-018-2743-0Open DOISearch in Google Scholar
Nonnenmühlen N, Burnic A, Bartella A, Lethaus B, Gerhards F, Ristow O, et al (2019). Comparison of mucosal and mucoperiosteal wound cover for the treatment of medication-related osteonecrosis of the jaw lesions: a retrospective cohort study. Clin Oral Investig 23:351–359, doi: 10.1007/s00784-018-2443-9.NonnenmühlenNBurnicABartellaALethausBGerhardsFRistowO2019Comparison of mucosal and mucoperiosteal wound cover for the treatment of medication-related osteonecrosis of the jaw lesions: a retrospective cohort study2335135910.1007/s00784-018-2443-9Open DOISearch in Google Scholar
Ristow O, Rückschloß T, Müller M, Berger M, Kargus S, Pautke C, et al (2019). Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J Craniomaxillofac Surg 47:491–499.RistowORückschloßTMüllerMBergerMKargusSPautkeC2019Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study47491499Search in Google Scholar
Jung SY, Suh HS, Park JW, Kwon JW (2019). Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw. Oral Dis 25:471–480.JungSYSuhHSParkJWKwonJW2019Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw25471480Search in Google Scholar
Katsarelis H, Shah NP, Dhariwal DK, Pazianas M (2015). Infection and medication-related osteonecrosis of the jaw. J Dental Res 94:534–539, doi: 10.1177/0022034515572021.KatsarelisHShahNPDhariwalDKPazianasM2015Infection and medication-related osteonecrosis of the jaw9453453910.1177/0022034515572021Open DOISearch in Google Scholar
Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D (2017). Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo 69:9–15, doi. 10.4081/reumatismo.207.983..FassioABertoldoFIdolazziLViapianaORossiniMGattiD2017Drug-induced osteonecrosis of the jaw: the state of the art6991510.4081/reumatismo.207.983Open DOISearch in Google Scholar
Chang J, Hakan AE, McCauley LK (2018). Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr Osteoporos Rep 16:584–595, doi.org/.10.1007/s11914-018-0474-4.ChangJHakanAEMcCauleyLK2018Current understanding of the pathophysiology of osteonecrosis of the jaw16584595doi.org/.10.1007/s11914-018-0474-4.Search in Google Scholar